This study is being done to learn more about the safety, effectiveness, and tolerability of Inaxaplin in participants with APOL1-mediated kidney disease (AMKD). People of African ancestry are more likely to have certain APOL1 variants and are more at risk for chronic kidney disease (CKD). Currently, treatment for CKD exists only to control some aspects of the disease, such as high blood pressure. However, it is important to also treat the worsening of the kidney function as well as the underlying cause of CKD. Inaxaplin is being studied to determine if it can slow or stop the worsening of kidney function and target the underlying cause of this disease. Inaxaplin is an investigational drug.
Blood collection, height, weight, electrocardiogram (ecg), urine collection, physical exam, taking investigational drug.
depends on visit $25-$250, parking paid
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA
Vimal Derebail
Medicine-Nephrology
Clinical or Medical
Interventional
Blood Pressure
Diabetes
Kidneys and Liver
24-2946
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
